data_2bao_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2bao _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.806 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.366 0 N-CA-C 107.213 -2.355 . . . . 0.0 107.213 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.8 mtmt -114.11 -14.08 12.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.481 -1.011 . . . . 0.0 109.828 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.787 HG11 ' N ' ' A' ' 5' ' ' LEU 0.396 1.5 p -89.66 -13.9 9.31 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 102.398 -3.186 . . . . 0.0 102.398 177.939 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.962 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 2.8 tt -50.59 -2.87 0.02 OUTLIER 'General case' 0 N--CA 1.379 -3.996 0 CA-C-N 108.611 -3.904 . . . . 0.0 110.844 -175.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.654 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.7 t -119.18 2.28 11.39 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.335 -1.346 . . . . 0.0 114.077 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.829 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -113.47 -46.19 3.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.543 -1.348 . . . . 0.0 107.639 -179.9 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.824 HD13 ' CZ ' ' A' ' 9' ' ' PHE 0.252 0.1 OUTLIER -62.57 5.49 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 124.44 2.066 . . . . 0.0 107.007 177.689 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.962 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 17.5 m-85 -99.63 1.45 43.6 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 111.861 -2.427 . . . . 0.0 107.541 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 36.79 -148.52 0.05 OUTLIER Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.578 ' ND2' ' O ' ' A' ' 10' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.367 -1.078 . . . . 0.0 109.423 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.533 ' C4 ' HD11 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.834 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.448 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -113.93 -16.23 12.22 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.459 -1.024 . . . . 0.0 109.648 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.813 HG13 ' N ' ' A' ' 5' ' ' LEU 0.386 1.4 p -86.86 -15.67 9.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 177.753 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.959 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.4 tt -50.08 -3.68 0.02 OUTLIER 'General case' 0 N--CA 1.383 -3.814 0 CA-C-N 108.584 -3.916 . . . . 0.0 111.788 -174.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.599 ' H ' ' C ' ' A' ' 4' ' ' VAL . 35.0 t -119.7 2.56 11.14 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 117.93 -1.508 . . . . 0.0 114.109 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.746 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -112.33 -41.8 3.83 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 -179.76 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.854 HD11 ' CZ ' ' A' ' 9' ' ' PHE 0.268 0.0 OUTLIER -68.24 4.32 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 124.581 2.134 . . . . 0.0 107.081 177.996 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.959 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 18.5 m-85 -97.55 1.28 48.74 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 111.57 -2.559 . . . . 0.0 106.588 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.604 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 9.75 -99.56 0.01 OUTLIER Glycine 0 N--CA 1.498 2.801 0 CA-C-N 113.951 -1.477 . . . . 0.0 111.063 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.634 ' N ' ' ND2' ' A' ' 11' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.36 -1.082 . . . . 0.0 109.9 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.564 ' C1 ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.85 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.542 1.75 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.6 mmtt -113.78 -15.68 12.39 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.393 -1.063 . . . . 0.0 109.334 179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.826 HG11 ' N ' ' A' ' 5' ' ' LEU 0.395 1.5 p -88.3 -14.99 9.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 N-CA-C 102.174 -3.269 . . . . 0.0 102.174 177.894 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 1.027 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.4 tt -50.3 -1.2 0.01 OUTLIER 'General case' 0 N--CA 1.389 -3.511 0 CA-C-N 109.419 -3.537 . . . . 0.0 110.174 -175.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.682 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 38.7 t -120.46 1.57 10.68 Favored 'General case' 0 CA--C 1.553 1.095 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 -179.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.918 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 3.2 ptpt -112.43 -48.41 3.02 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.421 -1.424 . . . . 0.0 108.737 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.947 HD12 ' CZ ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.05 7.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 CA-C-O 122.753 1.263 . . . . 0.0 111.372 -179.558 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.027 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -106.0 -19.98 13.56 Favored 'General case' 0 N--CA 1.52 3.042 0 C-N-CA 124.088 0.955 . . . . 0.0 109.022 179.62 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.73 -10.73 52.98 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.45 ' ND2' ' HB2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.14 -1.212 . . . . 0.0 109.482 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.63 ' C4 ' HD13 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.792 ' H ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.413 0 N-CA-C 107.203 -2.359 . . . . 0.0 107.203 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -111.65 -4.81 14.6 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 123.225 1.488 . . . . 0.0 107.592 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.821 HG11 ' N ' ' A' ' 5' ' ' LEU 0.409 1.3 p -90.95 -14.81 8.64 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 103.202 -2.888 . . . . 0.0 103.202 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.972 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 9.0 tt -54.3 -3.07 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.11 0 CA-C-N 109.888 -3.324 . . . . 0.0 110.401 -174.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.612 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 46.8 t -120.25 1.85 10.81 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 -179.068 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.814 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -112.41 -44.53 3.36 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.326 -1.483 . . . . 0.0 108.928 178.946 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.824 HD11 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -70.27 7.71 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 CA-C-O 123.208 1.48 . . . . 0.0 111.581 -179.492 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.037 ' CD1' ' N ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -104.38 1.32 30.05 Favored 'General case' 0 N--CA 1.513 2.712 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.819 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.89 -4.91 59.78 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.258 -1.142 . . . . 0.0 109.487 179.948 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.705 ' H41' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.871 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.67 0 N-CA-C 106.74 -2.544 . . . . 0.0 106.74 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.4 mtpp -113.48 -14.74 12.69 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.527 -0.984 . . . . 0.0 109.813 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.807 HG12 ' N ' ' A' ' 5' ' ' LEU 0.399 1.4 p -89.94 -13.56 9.34 Favored 'Isoleucine or valine' 0 C--O 1.187 -2.216 0 N-CA-C 102.249 -3.241 . . . . 0.0 102.249 178.084 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 1.0 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 5.3 tt -51.61 -1.24 0.02 OUTLIER 'General case' 0 N--CA 1.386 -3.654 0 CA-C-N 109.337 -3.574 . . . . 0.0 110.098 -175.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.661 ' H ' ' C ' ' A' ' 4' ' ' VAL . 33.2 t -120.32 2.04 10.78 Favored 'General case' 0 CA--C 1.554 1.117 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.888 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 7.0 ptpt -112.56 -48.04 3.04 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 120.505 -1.372 . . . . 0.0 108.571 179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.879 HD12 ' CE2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.85 6.17 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 CA-C-O 123.108 1.432 . . . . 0.0 111.431 -179.515 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.0 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -107.11 0.14 23.26 Favored 'General case' 0 N--CA 1.516 2.859 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.011 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.88 -34.12 0.22 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.577 HD21 ' C ' ' A' ' 7' ' ' LYS . 14.6 m-80 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.262 -1.14 . . . . 0.0 109.316 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.552 ' C1 ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.586 ' O ' ' CB ' ' A' ' 5' ' ' LEU . . . . . . . . 0 N--CA 1.494 2.545 0 CA-C-O 122.043 0.801 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.3 mtmt -112.97 -7.2 13.72 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 123.575 1.655 . . . . 0.0 107.311 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.78 HG11 ' N ' ' A' ' 5' ' ' LEU 0.437 1.3 p -86.53 -12.36 10.99 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.954 0 N-CA-C 101.097 -3.668 . . . . 0.0 101.097 176.35 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.963 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.1 tt -52.38 -3.66 0.02 OUTLIER 'General case' 1 N--CA 1.377 -4.118 0 CA-C-N 108.559 -3.928 . . . . 0.0 110.911 -174.159 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.628 ' H ' ' C ' ' A' ' 4' ' ' VAL . 28.3 t -120.34 3.26 10.83 Favored 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 117.934 -1.506 . . . . 0.0 113.831 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.804 ' C ' ' H ' ' A' ' 9' ' ' PHE . 1.7 ptpt -113.18 -43.93 3.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.499 -1.376 . . . . 0.0 107.705 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 1.025 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.288 0.1 OUTLIER -65.75 6.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 124.496 2.093 . . . . 0.0 106.923 177.711 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.025 ' CE1' HD13 ' A' ' 8' ' ' ILE . 18.3 m-85 -100.99 -15.52 17.45 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 111.339 -2.664 . . . . 0.0 108.892 176.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.561 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 29.14 33.25 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.683 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.168 -1.196 . . . . 0.0 109.354 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.566 ' H41' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.867 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.54 1.615 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.0 mtpp -113.59 -13.69 12.72 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.479 -1.012 . . . . 0.0 109.242 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.83 HG11 ' N ' ' A' ' 5' ' ' LEU 0.395 1.6 p -92.29 -15.2 8.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.992 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.7 tt -49.43 -0.55 0.01 OUTLIER 'General case' 0 N--CA 1.386 -3.65 0 CA-C-N 109.849 -3.342 . . . . 0.0 109.499 -176.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.727 ' H ' ' C ' ' A' ' 4' ' ' VAL . 42.7 t -118.84 -1.13 11.1 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 116.127 1.899 . . . . 0.0 116.127 -178.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.922 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 13.1 ptpt -111.0 -45.65 3.43 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 119.99 -1.694 . . . . 0.0 108.679 177.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.947 HD13 ' CE2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.25 5.35 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 123.359 1.552 . . . . 0.0 111.409 -177.45 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.992 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -110.6 -7.24 14.72 Favored 'General case' 0 N--CA 1.512 2.651 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.51 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 11' ' ' ASN . . . -130.66 39.14 1.84 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.661 ' ND2' ' O ' ' A' ' 7' ' ' LYS . 51.5 m-80 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.242 -1.152 . . . . 0.0 109.039 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.556 ' C1 ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.839 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.668 0 N-CA-C 108.172 -1.971 . . . . 0.0 108.172 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.2 mtpp -111.81 -17.03 13.04 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.615 1.198 . . . . 0.0 108.511 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.859 HG12 ' N ' ' A' ' 5' ' ' LEU 0.365 1.1 p -83.38 -19.35 9.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.262 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 177.6 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 1.001 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 5.6 tt -48.5 -5.02 0.01 OUTLIER 'General case' 0 N--CA 1.393 -3.284 0 CA-C-N 108.472 -3.967 . . . . 0.0 110.768 -175.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.652 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.9 t -122.44 5.82 9.59 Favored 'General case' 0 C--N 1.292 -1.908 0 C-N-CA 118.094 -1.442 . . . . 0.0 114.07 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.753 ' O ' ' N ' ' A' ' 10' ' ' GLY . 0.1 OUTLIER -113.86 -35.13 5.23 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.297 -1.502 . . . . 0.0 107.594 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.875 HD11 ' CE1' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -67.35 -6.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 124.657 2.17 . . . . 0.0 106.521 178.783 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.001 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 4.6 m-85 -92.89 -5.33 51.13 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 110.848 -2.887 . . . . 0.0 103.212 177.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.753 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 17.95 40.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.804 0 CA-C-N 111.82 -2.445 . . . . 0.0 110.69 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.746 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.345 -1.091 . . . . 0.0 109.147 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.737 ' C4 ' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.814 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.379 0 N-CA-C 106.79 -2.524 . . . . 0.0 106.79 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 10.6 mttp -113.57 -11.18 13.06 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.551 -0.97 . . . . 0.0 109.459 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.78 HG13 ' N ' ' A' ' 5' ' ' LEU 0.4 1.5 p -91.71 -13.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.22 0 N-CA-C 102.565 -3.124 . . . . 0.0 102.565 178.687 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.973 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.8 tt -51.75 -2.79 0.02 OUTLIER 'General case' 0 N--CA 1.382 -3.852 0 CA-C-N 108.624 -3.898 . . . . 0.0 110.827 -174.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.64 ' H ' ' C ' ' A' ' 4' ' ' VAL . 37.7 t -119.43 1.68 11.23 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.352 -1.339 . . . . 0.0 114.028 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.761 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -113.93 -42.56 3.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.485 -1.384 . . . . 0.0 108.236 -179.607 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.778 ' CD1' ' CE1' ' A' ' 9' ' ' PHE 0.251 0.1 OUTLIER -66.99 6.35 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-O 124.606 2.146 . . . . 0.0 107.052 178.204 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.973 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 31.7 m-85 -95.44 2.74 54.61 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 111.82 -2.446 . . . . 0.0 109.462 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.69 35.28 2.85 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.553 ' ND2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.207 -1.172 . . . . 0.0 109.429 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.537 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.774 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.533 1.191 0 N-CA-C 107.766 -2.134 . . . . 0.0 107.766 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 mmtp -110.79 -18.9 13.01 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 123.122 1.439 . . . . 0.0 108.366 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.799 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.362 2.2 p -77.89 -24.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.626 0 N-CA-C 102.008 -3.33 . . . . 0.0 102.008 176.292 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.981 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 10.2 tt -42.44 -2.78 0.0 OUTLIER 'General case' 0 N--CA 1.423 -1.8 0 CA-C-N 110.074 -3.239 . . . . 0.0 110.561 -177.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.716 ' H ' ' C ' ' A' ' 4' ' ' VAL . 26.5 t -124.97 4.55 8.0 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 116.987 2.217 . . . . 0.0 116.987 179.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.823 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 2.6 ptpt -111.85 -47.31 3.15 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 119.807 -1.808 . . . . 0.0 108.248 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.852 ' CD1' ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -50.94 -38.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 123.069 1.414 . . . . 0.0 110.246 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.03 ' CD1' ' N ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.63 -3.09 5.7 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.29 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.6 ' H ' ' C ' ' A' ' 8' ' ' ILE . . . 30.22 40.47 0.04 OUTLIER Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.152 -1.205 . . . . 0.0 109.504 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.731 ' C4 ' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.885 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.538 1.504 0 N-CA-C 107.294 -2.323 . . . . 0.0 107.294 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.8 mmtp -114.17 -14.28 12.34 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 122.337 1.065 . . . . 0.0 109.142 178.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.822 HG11 ' N ' ' A' ' 5' ' ' LEU 0.4 1.5 p -88.32 -14.31 9.65 Favored 'Isoleucine or valine' 0 C--O 1.186 -2.258 0 N-CA-C 102.102 -3.296 . . . . 0.0 102.102 177.825 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 1.015 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 4.5 tt -51.24 -3.09 0.02 OUTLIER 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 109.168 -3.651 . . . . 0.0 110.654 -175.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.645 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 34.1 t -119.98 2.22 10.97 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 115.748 1.758 . . . . 0.0 115.748 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.917 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -112.51 -46.67 3.14 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.377 -1.452 . . . . 0.0 108.701 179.167 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.85 ' CD1' ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -67.32 6.2 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 122.998 1.38 . . . . 0.0 111.491 -179.213 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.015 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -108.08 -19.47 13.49 Favored 'General case' 0 N--CA 1.517 2.894 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.501 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.11 -35.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . 0.697 ' H ' ' C ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 O-C-N 121.34 -1.094 . . . . 0.0 109.082 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.551 ' C1 ' ' CD1' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.836 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.532 1.13 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.16 -7.79 14.03 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.945 1.355 . . . . 0.0 107.475 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.805 HG13 ' N ' ' A' ' 5' ' ' LEU 0.4 1.5 p -94.92 -13.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.18 -2.586 0 N-CA-C 103.75 -2.685 . . . . 0.0 103.75 178.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.913 ' CA ' ' CZ ' ' A' ' 9' ' ' PHE . 8.2 tt -59.54 -1.46 0.24 Allowed 'General case' 0 N--CA 1.4 -2.953 0 CA-C-N 110.384 -3.098 . . . . 0.0 110.627 -173.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.647 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 33.8 t -120.27 2.14 10.82 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 115.756 1.762 . . . . 0.0 115.756 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.814 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 5.0 ptpt -112.76 -46.64 3.12 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 120.492 -1.38 . . . . 0.0 108.764 179.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 1.077 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -69.89 8.49 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 123.211 1.481 . . . . 0.0 111.693 -178.785 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 1.077 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -102.65 1.12 34.21 Favored 'General case' 0 N--CA 1.518 2.951 0 C-N-CA 124.35 1.06 . . . . 0.0 108.664 179.568 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.57 -0.22 76.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.269 -1.136 . . . . 0.0 109.642 -179.876 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MYR . . . . . 0.652 ' H41' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.839 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.366 0 N-CA-C 107.213 -2.355 . . . . 0.0 107.213 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.8 mtmt -114.11 -14.08 12.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.481 -1.011 . . . . 0.0 109.828 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.766 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.396 1.5 p -89.66 -13.9 9.31 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 102.398 -3.186 . . . . 0.0 102.398 177.939 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.962 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 2.8 tt -50.59 -2.87 0.02 OUTLIER 'General case' 0 N--CA 1.379 -3.996 0 CA-C-N 108.611 -3.904 . . . . 0.0 110.844 -175.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.623 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.7 t -119.18 2.28 11.39 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.335 -1.346 . . . . 0.0 114.077 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.794 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -113.47 -46.19 3.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.543 -1.348 . . . . 0.0 107.639 -179.9 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.175 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.252 0.1 OUTLIER -62.57 5.49 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 124.44 2.066 . . . . 0.0 107.007 177.689 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.175 ' CE1' HD13 ' A' ' 8' ' ' ILE . 17.5 m-85 -99.63 1.45 43.6 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 111.861 -2.427 . . . . 0.0 107.541 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 36.79 -148.52 0.05 OUTLIER Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.578 ' ND2' ' O ' ' A' ' 10' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.367 -1.078 . . . . 0.0 109.423 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.832 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.88 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.448 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -113.93 -16.23 12.22 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.459 -1.024 . . . . 0.0 109.648 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.733 HG23 ' HD2' ' A' ' 7' ' ' LYS 0.386 1.4 p -86.86 -15.67 9.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 177.753 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.959 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.4 tt -50.08 -3.68 0.02 OUTLIER 'General case' 0 N--CA 1.383 -3.814 0 CA-C-N 108.584 -3.916 . . . . 0.0 111.788 -174.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.568 ' H ' ' C ' ' A' ' 4' ' ' VAL . 35.0 t -119.7 2.56 11.14 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 117.93 -1.508 . . . . 0.0 114.109 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.733 ' HD2' HG23 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -112.33 -41.8 3.83 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 -179.76 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.238 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.268 0.0 OUTLIER -68.24 4.32 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 124.581 2.134 . . . . 0.0 107.081 177.996 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.238 ' CE1' HD13 ' A' ' 8' ' ' ILE . 18.5 m-85 -97.55 1.28 48.74 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 111.57 -2.559 . . . . 0.0 106.588 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.604 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 9.75 -99.56 0.01 OUTLIER Glycine 0 N--CA 1.498 2.801 0 CA-C-N 113.951 -1.477 . . . . 0.0 111.063 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.634 ' ND2' ' N ' ' A' ' 11' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.36 -1.082 . . . . 0.0 109.9 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.77 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.885 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.542 1.75 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.6 mmtt -113.78 -15.68 12.39 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.393 -1.063 . . . . 0.0 109.334 179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.715 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.395 1.5 p -88.3 -14.99 9.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 N-CA-C 102.174 -3.269 . . . . 0.0 102.174 177.894 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.027 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.4 tt -50.3 -1.2 0.01 OUTLIER 'General case' 0 N--CA 1.389 -3.511 0 CA-C-N 109.419 -3.537 . . . . 0.0 110.174 -175.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.682 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 38.7 t -120.46 1.57 10.68 Favored 'General case' 0 CA--C 1.553 1.095 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 -179.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.945 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 3.2 ptpt -112.43 -48.41 3.02 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.421 -1.424 . . . . 0.0 108.737 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.972 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.05 7.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 CA-C-O 122.753 1.263 . . . . 0.0 111.372 -179.558 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.027 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -106.0 -19.98 13.56 Favored 'General case' 0 N--CA 1.52 3.042 0 C-N-CA 124.088 0.955 . . . . 0.0 109.022 179.62 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.73 -10.73 52.98 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.14 -1.212 . . . . 0.0 109.482 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.695 ' H41' HG13 ' A' ' 4' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.678 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.413 0 N-CA-C 107.203 -2.359 . . . . 0.0 107.203 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -111.65 -4.81 14.6 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 123.225 1.488 . . . . 0.0 107.592 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.728 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.409 1.3 p -90.95 -14.81 8.64 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 103.202 -2.888 . . . . 0.0 103.202 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.991 HD23 ' O ' ' A' ' 5' ' ' LEU . 9.0 tt -54.3 -3.07 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.11 0 CA-C-N 109.888 -3.324 . . . . 0.0 110.401 -174.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.612 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 46.8 t -120.25 1.85 10.81 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 -179.068 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.814 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -112.41 -44.53 3.36 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.326 -1.483 . . . . 0.0 108.928 178.946 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.052 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -70.27 7.71 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 CA-C-O 123.208 1.48 . . . . 0.0 111.581 -179.492 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.052 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -104.38 1.32 30.05 Favored 'General case' 0 N--CA 1.513 2.712 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.819 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.89 -4.91 59.78 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.258 -1.142 . . . . 0.0 109.487 179.948 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.756 ' H42' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.908 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.67 0 N-CA-C 106.74 -2.544 . . . . 0.0 106.74 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.4 mtpp -113.48 -14.74 12.69 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.527 -0.984 . . . . 0.0 109.813 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.722 HG13 ' H41' ' A' ' 1' ' ' MYR 0.399 1.4 p -89.94 -13.56 9.34 Favored 'Isoleucine or valine' 0 C--O 1.187 -2.216 0 N-CA-C 102.249 -3.241 . . . . 0.0 102.249 178.084 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.0 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 5.3 tt -51.61 -1.24 0.02 OUTLIER 'General case' 0 N--CA 1.386 -3.654 0 CA-C-N 109.337 -3.574 . . . . 0.0 110.098 -175.597 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.642 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 33.2 t -120.32 2.04 10.78 Favored 'General case' 0 CA--C 1.554 1.117 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.913 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 7.0 ptpt -112.56 -48.04 3.04 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 120.505 -1.372 . . . . 0.0 108.571 179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.008 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.85 6.17 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 CA-C-O 123.108 1.432 . . . . 0.0 111.431 -179.515 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.008 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -107.11 0.14 23.26 Favored 'General case' 0 N--CA 1.516 2.859 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.011 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.88 -34.12 0.22 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.421 ' OD1' ' O ' ' A' ' 7' ' ' LYS . 10.5 m120 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.262 -1.14 . . . . 0.0 109.316 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.796 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.586 ' O ' ' CB ' ' A' ' 5' ' ' LEU . . . . . . . . 0 N--CA 1.494 2.545 0 CA-C-O 122.043 0.801 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.454 ' N ' HG12 ' A' ' 4' ' ' VAL . 4.3 mtmt -112.97 -7.2 13.72 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 123.575 1.655 . . . . 0.0 107.311 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.77 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.437 1.3 p -86.53 -12.36 10.99 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.954 0 N-CA-C 101.097 -3.668 . . . . 0.0 101.097 176.35 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.963 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.1 tt -52.38 -3.66 0.02 OUTLIER 'General case' 1 N--CA 1.377 -4.118 0 CA-C-N 108.559 -3.928 . . . . 0.0 110.911 -174.159 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.575 ' H ' ' C ' ' A' ' 4' ' ' VAL . 28.3 t -120.34 3.26 10.83 Favored 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 117.934 -1.506 . . . . 0.0 113.831 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.801 ' C ' ' H ' ' A' ' 9' ' ' PHE . 1.7 ptpt -113.18 -43.93 3.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.499 -1.376 . . . . 0.0 107.705 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.096 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.288 0.1 OUTLIER -65.75 6.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 124.496 2.093 . . . . 0.0 106.923 177.711 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.096 ' CE1' HD13 ' A' ' 8' ' ' ILE . 18.3 m-85 -100.99 -15.52 17.45 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 111.339 -2.664 . . . . 0.0 108.892 176.261 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.561 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 29.14 33.25 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.683 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.168 -1.196 . . . . 0.0 109.354 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.899 ' O1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.912 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.54 1.615 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.0 mtpp -113.59 -13.69 12.72 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.479 -1.012 . . . . 0.0 109.242 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.756 HG13 ' H41' ' A' ' 1' ' ' MYR 0.395 1.6 p -92.29 -15.2 8.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.992 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.7 tt -49.43 -0.55 0.01 OUTLIER 'General case' 0 N--CA 1.386 -3.65 0 CA-C-N 109.849 -3.342 . . . . 0.0 109.499 -176.109 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.697 ' H ' ' C ' ' A' ' 4' ' ' VAL . 42.7 t -118.84 -1.13 11.1 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 116.127 1.899 . . . . 0.0 116.127 -178.696 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.911 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 13.1 ptpt -111.0 -45.65 3.43 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 119.99 -1.694 . . . . 0.0 108.679 177.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.05 HD13 ' CE2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.25 5.35 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 123.359 1.552 . . . . 0.0 111.409 -177.45 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.05 ' CE2' HD13 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -110.6 -7.24 14.72 Favored 'General case' 0 N--CA 1.512 2.651 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.51 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 11' ' ' ASN . . . -130.66 39.14 1.84 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.661 ' ND2' ' O ' ' A' ' 7' ' ' LYS . 51.5 m-80 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.242 -1.152 . . . . 0.0 109.039 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.795 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.874 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.668 0 N-CA-C 108.172 -1.971 . . . . 0.0 108.172 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.2 mtpp -111.81 -17.03 13.04 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.615 1.198 . . . . 0.0 108.511 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.649 HG13 ' N ' ' A' ' 5' ' ' LEU 0.365 1.1 p -83.38 -19.35 9.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.262 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 177.6 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.001 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 5.6 tt -48.5 -5.02 0.01 OUTLIER 'General case' 0 N--CA 1.393 -3.284 0 CA-C-N 108.472 -3.967 . . . . 0.0 110.768 -175.08 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.622 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.9 t -122.44 5.82 9.59 Favored 'General case' 0 C--N 1.292 -1.908 0 C-N-CA 118.094 -1.442 . . . . 0.0 114.07 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.753 ' O ' ' N ' ' A' ' 10' ' ' GLY . 0.1 OUTLIER -113.86 -35.13 5.23 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.297 -1.502 . . . . 0.0 107.594 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.815 HD13 ' CE1' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -67.35 -6.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 124.657 2.17 . . . . 0.0 106.521 178.783 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.001 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 4.6 m-85 -92.89 -5.33 51.13 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 110.848 -2.887 . . . . 0.0 103.212 177.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.753 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 17.95 40.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.804 0 CA-C-N 111.82 -2.445 . . . . 0.0 110.69 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.746 ' N ' ' O ' ' A' ' 9' ' ' PHE . 3.0 p-10 . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.345 -1.091 . . . . 0.0 109.147 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.773 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.845 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.379 0 N-CA-C 106.79 -2.524 . . . . 0.0 106.79 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 10.6 mttp -113.57 -11.18 13.06 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.551 -0.97 . . . . 0.0 109.459 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.748 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.4 1.5 p -91.71 -13.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.22 0 N-CA-C 102.565 -3.124 . . . . 0.0 102.565 178.687 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.973 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.8 tt -51.75 -2.79 0.02 OUTLIER 'General case' 0 N--CA 1.382 -3.852 0 CA-C-N 108.624 -3.898 . . . . 0.0 110.827 -174.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.604 ' H ' ' C ' ' A' ' 4' ' ' VAL . 37.7 t -119.43 1.68 11.23 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.352 -1.339 . . . . 0.0 114.028 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.743 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -113.93 -42.56 3.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.485 -1.384 . . . . 0.0 108.236 -179.607 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.122 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.251 0.1 OUTLIER -66.99 6.35 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-O 124.606 2.146 . . . . 0.0 107.052 178.204 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.122 ' CE1' HD13 ' A' ' 8' ' ' ILE . 31.7 m-85 -95.44 2.74 54.61 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 111.82 -2.446 . . . . 0.0 109.462 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.69 35.28 2.85 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.553 ' ND2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.207 -1.172 . . . . 0.0 109.429 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.818 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.787 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.533 1.191 0 N-CA-C 107.766 -2.134 . . . . 0.0 107.766 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 mmtp -110.79 -18.9 13.01 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 123.122 1.439 . . . . 0.0 108.366 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.813 HG13 ' N ' ' A' ' 5' ' ' LEU 0.362 2.2 p -77.89 -24.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.626 0 N-CA-C 102.008 -3.33 . . . . 0.0 102.008 176.292 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.981 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 10.2 tt -42.44 -2.78 0.0 OUTLIER 'General case' 0 N--CA 1.423 -1.8 0 CA-C-N 110.074 -3.239 . . . . 0.0 110.561 -177.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.671 ' N ' ' O ' ' A' ' 4' ' ' VAL . 26.5 t -124.97 4.55 8.0 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 116.987 2.217 . . . . 0.0 116.987 179.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.823 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 2.6 ptpt -111.85 -47.31 3.15 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 119.807 -1.808 . . . . 0.0 108.248 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -50.94 -38.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 123.069 1.414 . . . . 0.0 110.246 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.03 ' CD1' ' N ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.63 -3.09 5.7 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.29 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.564 ' H ' ' C ' ' A' ' 8' ' ' ILE . . . 30.22 40.47 0.04 OUTLIER Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.152 -1.205 . . . . 0.0 109.504 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.79 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.913 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.538 1.504 0 N-CA-C 107.294 -2.323 . . . . 0.0 107.294 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.8 mmtp -114.17 -14.28 12.34 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 122.337 1.065 . . . . 0.0 109.142 178.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.704 HG13 ' H41' ' A' ' 1' ' ' MYR 0.4 1.5 p -88.32 -14.31 9.65 Favored 'Isoleucine or valine' 0 C--O 1.186 -2.258 0 N-CA-C 102.102 -3.296 . . . . 0.0 102.102 177.825 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.015 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 4.5 tt -51.24 -3.09 0.02 OUTLIER 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 109.168 -3.651 . . . . 0.0 110.654 -175.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.645 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 34.1 t -119.98 2.22 10.97 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 115.748 1.758 . . . . 0.0 115.748 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.943 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -112.51 -46.67 3.14 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.377 -1.452 . . . . 0.0 108.701 179.167 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.98 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -67.32 6.2 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 122.998 1.38 . . . . 0.0 111.491 -179.213 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.015 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -108.08 -19.47 13.49 Favored 'General case' 0 N--CA 1.517 2.894 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.501 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.11 -35.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.665 ' H ' ' C ' ' A' ' 9' ' ' PHE . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 O-C-N 121.34 -1.094 . . . . 0.0 109.082 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.94 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.857 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.532 1.13 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.16 -7.79 14.03 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.945 1.355 . . . . 0.0 107.475 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.708 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.4 1.5 p -94.92 -13.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.18 -2.586 0 N-CA-C 103.75 -2.685 . . . . 0.0 103.75 178.975 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.007 ' HA ' ' CZ ' ' A' ' 9' ' ' PHE . 8.2 tt -59.54 -1.46 0.24 Allowed 'General case' 0 N--CA 1.4 -2.953 0 CA-C-N 110.384 -3.098 . . . . 0.0 110.627 -173.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.647 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 33.8 t -120.27 2.14 10.82 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 115.756 1.762 . . . . 0.0 115.756 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.867 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 5.0 ptpt -112.76 -46.64 3.12 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 120.492 -1.38 . . . . 0.0 108.764 179.33 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 1.053 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -69.89 8.49 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 123.211 1.481 . . . . 0.0 111.693 -178.785 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 1.053 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -102.65 1.12 34.21 Favored 'General case' 0 N--CA 1.518 2.951 0 C-N-CA 124.35 1.06 . . . . 0.0 108.664 179.568 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.57 -0.22 76.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.269 -1.136 . . . . 0.0 109.642 -179.876 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MYR . . . . . 0.701 ' H42' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.839 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.366 0 N-CA-C 107.213 -2.355 . . . . 0.0 107.213 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 15.8 mtmt -114.11 -14.08 12.38 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.481 -1.011 . . . . 0.0 109.828 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.766 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.396 1.5 p -89.66 -13.9 9.31 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 102.398 -3.186 . . . . 0.0 102.398 177.939 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.962 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 2.8 tt -50.59 -2.87 0.02 OUTLIER 'General case' 0 N--CA 1.379 -3.996 0 CA-C-N 108.611 -3.904 . . . . 0.0 110.844 -175.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.623 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.7 t -119.18 2.28 11.39 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.335 -1.346 . . . . 0.0 114.077 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.794 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -113.47 -46.19 3.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.543 -1.348 . . . . 0.0 107.639 -179.9 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.175 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.252 0.1 OUTLIER -62.57 5.49 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 CA-C-O 124.44 2.066 . . . . 0.0 107.007 177.689 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.175 ' CE1' HD13 ' A' ' 8' ' ' ILE . 17.5 m-85 -99.63 1.45 43.6 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 111.861 -2.427 . . . . 0.0 107.541 176.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 36.79 -148.52 0.05 OUTLIER Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.578 ' ND2' ' O ' ' A' ' 10' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.537 0 O-C-N 121.367 -1.078 . . . . 0.0 109.423 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.832 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.88 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.448 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.9 mtmt -113.93 -16.23 12.22 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.459 -1.024 . . . . 0.0 109.648 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.733 HG23 ' HD2' ' A' ' 7' ' ' LYS 0.386 1.4 p -86.86 -15.67 9.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 177.753 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.959 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.4 tt -50.08 -3.68 0.02 OUTLIER 'General case' 0 N--CA 1.383 -3.814 0 CA-C-N 108.584 -3.916 . . . . 0.0 111.788 -174.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.568 ' H ' ' C ' ' A' ' 4' ' ' VAL . 35.0 t -119.7 2.56 11.14 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 117.93 -1.508 . . . . 0.0 114.109 -179.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.733 ' HD2' HG23 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -112.33 -41.8 3.83 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 -179.76 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.238 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.268 0.0 OUTLIER -68.24 4.32 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 124.581 2.134 . . . . 0.0 107.081 177.996 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.238 ' CE1' HD13 ' A' ' 8' ' ' ILE . 18.5 m-85 -97.55 1.28 48.74 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 111.57 -2.559 . . . . 0.0 106.588 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.604 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 9.75 -99.56 0.01 OUTLIER Glycine 0 N--CA 1.498 2.801 0 CA-C-N 113.951 -1.477 . . . . 0.0 111.063 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.634 ' ND2' ' N ' ' A' ' 11' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.36 -1.082 . . . . 0.0 109.9 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.77 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.885 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.542 1.75 0 N-CA-C 107.733 -2.147 . . . . 0.0 107.733 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.6 mmtt -113.78 -15.68 12.39 Favored 'General case' 0 N--CA 1.505 2.277 0 O-C-N 121.393 -1.063 . . . . 0.0 109.334 179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.715 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.395 1.5 p -88.3 -14.99 9.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.263 0 N-CA-C 102.174 -3.269 . . . . 0.0 102.174 177.894 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.027 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.4 tt -50.3 -1.2 0.01 OUTLIER 'General case' 0 N--CA 1.389 -3.511 0 CA-C-N 109.419 -3.537 . . . . 0.0 110.174 -175.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.682 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 38.7 t -120.46 1.57 10.68 Favored 'General case' 0 CA--C 1.553 1.095 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 -179.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.945 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 3.2 ptpt -112.43 -48.41 3.02 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 120.421 -1.424 . . . . 0.0 108.737 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.972 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.05 7.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 CA-C-O 122.753 1.263 . . . . 0.0 111.372 -179.558 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.027 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -106.0 -19.98 13.56 Favored 'General case' 0 N--CA 1.52 3.042 0 C-N-CA 124.088 0.955 . . . . 0.0 109.022 179.62 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 103.73 -10.73 52.98 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.472 ' ND2' ' HB2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.14 -1.212 . . . . 0.0 109.482 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.695 ' H41' HG13 ' A' ' 4' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.678 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.537 1.413 0 N-CA-C 107.203 -2.359 . . . . 0.0 107.203 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -111.65 -4.81 14.6 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 123.225 1.488 . . . . 0.0 107.592 178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.728 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.409 1.3 p -90.95 -14.81 8.64 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.755 0 N-CA-C 103.202 -2.888 . . . . 0.0 103.202 178.13 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.991 HD23 ' O ' ' A' ' 5' ' ' LEU . 9.0 tt -54.3 -3.07 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.11 0 CA-C-N 109.888 -3.324 . . . . 0.0 110.401 -174.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.612 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 46.8 t -120.25 1.85 10.81 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 115.928 1.825 . . . . 0.0 115.928 -179.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.814 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 0.2 OUTLIER -112.41 -44.53 3.36 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.326 -1.483 . . . . 0.0 108.928 178.946 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.052 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -70.27 7.71 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 CA-C-O 123.208 1.48 . . . . 0.0 111.581 -179.492 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.052 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -104.38 1.32 30.05 Favored 'General case' 0 N--CA 1.513 2.712 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.819 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 78.89 -4.91 59.78 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.258 -1.142 . . . . 0.0 109.487 179.948 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.756 ' H42' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.908 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.67 0 N-CA-C 106.74 -2.544 . . . . 0.0 106.74 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 2.4 mtpp -113.48 -14.74 12.69 Favored 'General case' 0 N--CA 1.505 2.279 0 O-C-N 121.527 -0.984 . . . . 0.0 109.813 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.722 HG13 ' H41' ' A' ' 1' ' ' MYR 0.399 1.4 p -89.94 -13.56 9.34 Favored 'Isoleucine or valine' 0 C--O 1.187 -2.216 0 N-CA-C 102.249 -3.241 . . . . 0.0 102.249 178.084 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.0 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 5.3 tt -51.61 -1.24 0.02 OUTLIER 'General case' 0 N--CA 1.386 -3.654 0 CA-C-N 109.337 -3.574 . . . . 0.0 110.098 -175.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.642 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 33.2 t -120.32 2.04 10.78 Favored 'General case' 0 CA--C 1.554 1.117 0 N-CA-C 115.733 1.753 . . . . 0.0 115.733 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.913 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 7.0 ptpt -112.56 -48.04 3.04 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 120.505 -1.372 . . . . 0.0 108.571 179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.008 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.85 6.17 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 CA-C-O 123.108 1.432 . . . . 0.0 111.431 -179.515 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.008 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -107.11 0.14 23.26 Favored 'General case' 0 N--CA 1.516 2.859 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 179.011 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -136.88 -34.12 0.22 Allowed Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.609 HD22 ' C ' ' A' ' 7' ' ' LYS . 14.6 m-80 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.262 -1.14 . . . . 0.0 109.316 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.796 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.586 ' O ' ' CB ' ' A' ' 5' ' ' LEU . . . . . . . . 0 N--CA 1.494 2.545 0 CA-C-O 122.043 0.801 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.454 ' N ' HG12 ' A' ' 4' ' ' VAL . 4.3 mtmt -112.97 -7.2 13.72 Favored 'General case' 0 N--CA 1.499 2.017 0 CA-C-O 123.575 1.655 . . . . 0.0 107.311 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.77 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.437 1.3 p -86.53 -12.36 10.99 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.954 0 N-CA-C 101.097 -3.668 . . . . 0.0 101.097 176.35 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.963 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.1 tt -52.38 -3.66 0.02 OUTLIER 'General case' 1 N--CA 1.377 -4.118 0 CA-C-N 108.559 -3.928 . . . . 0.0 110.911 -174.159 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.575 ' H ' ' C ' ' A' ' 4' ' ' VAL . 28.3 t -120.34 3.26 10.83 Favored 'General case' 0 C--N 1.288 -2.077 0 C-N-CA 117.934 -1.506 . . . . 0.0 113.831 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.801 ' C ' ' H ' ' A' ' 9' ' ' PHE . 1.7 ptpt -113.18 -43.93 3.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.499 -1.376 . . . . 0.0 107.705 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.096 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.288 0.1 OUTLIER -65.75 6.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 124.496 2.093 . . . . 0.0 106.923 177.711 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.096 ' CE1' HD13 ' A' ' 8' ' ' ILE . 18.3 m-85 -100.99 -15.52 17.45 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 111.339 -2.664 . . . . 0.0 108.892 176.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.561 ' C ' ' O ' ' A' ' 9' ' ' PHE . . . 29.14 33.25 0.01 OUTLIER Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.683 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.168 -1.196 . . . . 0.0 109.354 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.899 ' O1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.912 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.54 1.615 0 N-CA-C 107.094 -2.402 . . . . 0.0 107.094 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.0 mtpp -113.59 -13.69 12.72 Favored 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.479 -1.012 . . . . 0.0 109.242 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.756 HG13 ' H41' ' A' ' 1' ' ' MYR 0.395 1.6 p -92.29 -15.2 8.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.249 0 N-CA-C 102.766 -3.05 . . . . 0.0 102.766 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.992 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 3.7 tt -49.43 -0.55 0.01 OUTLIER 'General case' 0 N--CA 1.386 -3.65 0 CA-C-N 109.849 -3.342 . . . . 0.0 109.499 -176.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.697 ' H ' ' C ' ' A' ' 4' ' ' VAL . 42.7 t -118.84 -1.13 11.1 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 116.127 1.899 . . . . 0.0 116.127 -178.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.911 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 13.1 ptpt -111.0 -45.65 3.43 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 119.99 -1.694 . . . . 0.0 108.679 177.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.05 HD13 ' CE2' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -65.25 5.35 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-O 123.359 1.552 . . . . 0.0 111.409 -177.45 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.05 ' CE2' HD13 ' A' ' 8' ' ' ILE . 0.0 OUTLIER -110.6 -7.24 14.72 Favored 'General case' 0 N--CA 1.512 2.651 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.51 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 11' ' ' ASN . . . -130.66 39.14 1.84 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.661 ' ND2' ' O ' ' A' ' 7' ' ' LYS . 51.5 m-80 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.242 -1.152 . . . . 0.0 109.039 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.795 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.874 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.541 1.668 0 N-CA-C 108.172 -1.971 . . . . 0.0 108.172 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.2 mtpp -111.81 -17.03 13.04 Favored 'General case' 0 N--CA 1.501 2.092 0 CA-C-O 122.615 1.198 . . . . 0.0 108.511 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.649 HG13 ' N ' ' A' ' 5' ' ' LEU 0.365 1.1 p -83.38 -19.35 9.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.262 0 N-CA-C 103.35 -2.833 . . . . 0.0 103.35 177.6 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.001 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 5.6 tt -48.5 -5.02 0.01 OUTLIER 'General case' 0 N--CA 1.393 -3.284 0 CA-C-N 108.472 -3.967 . . . . 0.0 110.768 -175.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.622 ' H ' ' C ' ' A' ' 4' ' ' VAL . 45.9 t -122.44 5.82 9.59 Favored 'General case' 0 C--N 1.292 -1.908 0 C-N-CA 118.094 -1.442 . . . . 0.0 114.07 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.753 ' O ' ' N ' ' A' ' 10' ' ' GLY . 0.1 OUTLIER -113.86 -35.13 5.23 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.297 -1.502 . . . . 0.0 107.594 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.815 HD13 ' CE1' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -67.35 -6.98 5.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 124.657 2.17 . . . . 0.0 106.521 178.783 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.001 ' CE1' ' C ' ' A' ' 5' ' ' LEU . 4.6 m-85 -92.89 -5.33 51.13 Favored 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 110.848 -2.887 . . . . 0.0 103.212 177.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.753 ' N ' ' O ' ' A' ' 7' ' ' LYS . . . 17.95 40.46 0.01 OUTLIER Glycine 0 N--CA 1.498 2.804 0 CA-C-N 111.82 -2.445 . . . . 0.0 110.69 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.746 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 O-C-N 121.345 -1.091 . . . . 0.0 109.147 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.773 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.845 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.536 1.379 0 N-CA-C 106.79 -2.524 . . . . 0.0 106.79 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 10.6 mttp -113.57 -11.18 13.06 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.551 -0.97 . . . . 0.0 109.459 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.748 HG22 ' CG2' ' A' ' 8' ' ' ILE 0.4 1.5 p -91.71 -13.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.22 0 N-CA-C 102.565 -3.124 . . . . 0.0 102.565 178.687 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.973 ' C ' ' CE1' ' A' ' 9' ' ' PHE . 3.8 tt -51.75 -2.79 0.02 OUTLIER 'General case' 0 N--CA 1.382 -3.852 0 CA-C-N 108.624 -3.898 . . . . 0.0 110.827 -174.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.604 ' H ' ' C ' ' A' ' 4' ' ' VAL . 37.7 t -119.43 1.68 11.23 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.352 -1.339 . . . . 0.0 114.028 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.743 ' C ' ' H ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -113.93 -42.56 3.37 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.485 -1.384 . . . . 0.0 108.236 -179.607 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.122 HD13 ' CE1' ' A' ' 9' ' ' PHE 0.251 0.1 OUTLIER -66.99 6.35 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-O 124.606 2.146 . . . . 0.0 107.052 178.204 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.122 ' CE1' HD13 ' A' ' 8' ' ' ILE . 31.7 m-85 -95.44 2.74 54.61 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 111.82 -2.446 . . . . 0.0 109.462 177.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 106.69 35.28 2.85 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.553 ' ND2' ' O ' ' A' ' 6' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.207 -1.172 . . . . 0.0 109.429 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.818 ' C4 ' HD12 ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.787 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.533 1.191 0 N-CA-C 107.766 -2.134 . . . . 0.0 107.766 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 mmtp -110.79 -18.9 13.01 Favored 'General case' 0 N--CA 1.499 2.006 0 CA-C-O 123.122 1.439 . . . . 0.0 108.366 178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.813 HG13 ' N ' ' A' ' 5' ' ' LEU 0.362 2.2 p -77.89 -24.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.626 0 N-CA-C 102.008 -3.33 . . . . 0.0 102.008 176.292 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.981 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 10.2 tt -42.44 -2.78 0.0 OUTLIER 'General case' 0 N--CA 1.423 -1.8 0 CA-C-N 110.074 -3.239 . . . . 0.0 110.561 -177.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.671 ' N ' ' O ' ' A' ' 4' ' ' VAL . 26.5 t -124.97 4.55 8.0 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 116.987 2.217 . . . . 0.0 116.987 179.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.823 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 2.6 ptpt -111.85 -47.31 3.15 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 119.807 -1.808 . . . . 0.0 108.248 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -50.94 -38.0 17.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 123.069 1.414 . . . . 0.0 110.246 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.03 ' CD1' ' N ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -66.63 -3.09 5.7 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 177.29 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.564 ' H ' ' C ' ' A' ' 8' ' ' ILE . . . 30.22 40.47 0.04 OUTLIER Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 9' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.152 -1.205 . . . . 0.0 109.504 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.79 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.913 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.538 1.504 0 N-CA-C 107.294 -2.323 . . . . 0.0 107.294 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.8 mmtp -114.17 -14.28 12.34 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 122.337 1.065 . . . . 0.0 109.142 178.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.704 HG13 ' H41' ' A' ' 1' ' ' MYR 0.4 1.5 p -88.32 -14.31 9.65 Favored 'Isoleucine or valine' 0 C--O 1.186 -2.258 0 N-CA-C 102.102 -3.296 . . . . 0.0 102.102 177.825 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.015 ' C ' ' CZ ' ' A' ' 9' ' ' PHE . 4.5 tt -51.24 -3.09 0.02 OUTLIER 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 109.168 -3.651 . . . . 0.0 110.654 -175.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.645 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 34.1 t -119.98 2.22 10.97 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 115.748 1.758 . . . . 0.0 115.748 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.943 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -112.51 -46.67 3.14 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.377 -1.452 . . . . 0.0 108.701 179.167 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.98 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -67.32 6.2 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 CA-C-O 122.998 1.38 . . . . 0.0 111.491 -179.213 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.015 ' CZ ' ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -108.08 -19.47 13.49 Favored 'General case' 0 N--CA 1.517 2.894 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.501 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.11 -35.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.665 ' H ' ' C ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.386 0 O-C-N 121.34 -1.094 . . . . 0.0 109.082 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.94 ' C1 ' HD12 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.857 ' N ' ' HB2' ' A' ' 5' ' ' LEU . . . . . . . . 0 CA--C 1.532 1.13 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -112.16 -7.79 14.03 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.945 1.355 . . . . 0.0 107.475 178.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.708 ' O ' ' CE1' ' A' ' 9' ' ' PHE 0.4 1.5 p -94.92 -13.48 8.28 Favored 'Isoleucine or valine' 0 C--O 1.18 -2.586 0 N-CA-C 103.75 -2.685 . . . . 0.0 103.75 178.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.007 ' HA ' ' CZ ' ' A' ' 9' ' ' PHE . 8.2 tt -59.54 -1.46 0.24 Allowed 'General case' 0 N--CA 1.4 -2.953 0 CA-C-N 110.384 -3.098 . . . . 0.0 110.627 -173.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.647 ' N ' ' CE1' ' A' ' 9' ' ' PHE . 33.8 t -120.27 2.14 10.82 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 115.756 1.762 . . . . 0.0 115.756 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.867 ' H ' ' HE1' ' A' ' 9' ' ' PHE . 5.0 ptpt -112.76 -46.64 3.12 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 120.492 -1.38 . . . . 0.0 108.764 179.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 1.053 HD13 ' CZ ' ' A' ' 9' ' ' PHE . 0.1 OUTLIER -69.89 8.49 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 CA-C-O 123.211 1.481 . . . . 0.0 111.693 -178.785 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 1.053 ' CZ ' HD13 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -102.65 1.12 34.21 Favored 'General case' 0 N--CA 1.518 2.951 0 C-N-CA 124.35 1.06 . . . . 0.0 108.664 179.568 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.57 -0.22 76.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.269 -1.136 . . . . 0.0 109.642 -179.876 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MYR . . . . . 0.701 ' H42' ' CD1' ' A' ' 8' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_